Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Receivables - Other: 2017-2024

Historic Receivables - Other for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $20.0 million.

  • Arcus Biosciences' Receivables - Other fell 31.25% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 31.25%. This contributed to the annual value of $20.0 million for FY2024, which is 47.37% down from last year.
  • According to the latest figures from FY2024, Arcus Biosciences' Receivables - Other is $20.0 million, which was down 47.37% from $38.0 million recorded in FY2023.
  • Over the past 5 years, Arcus Biosciences' Receivables - Other peaked at $745.0 million during FY2021, and registered a low of $1.0 million during FY2020.
  • For the 3-year period, Arcus Biosciences' Receivables - Other averaged around $32.3 million, with its median value being $38.0 million (2023).
  • Per our database at Business Quant, Arcus Biosciences' Receivables - Other surged by 70,920.02% in 2021 and then crashed by 94.77% in 2022.
  • Over the past 5 years, Arcus Biosciences' Receivables - Other (Yearly) stood at $1.0 million in 2020, then soared by 70,920.02% to $745.0 million in 2021, then plummeted by 94.77% to $39.0 million in 2022, then declined by 2.56% to $38.0 million in 2023, then plummeted by 47.37% to $20.0 million in 2024.